- Home
- CNO vs DNLI Comparison
CNO vs DNLI Comparison
Compare CNO & DNLI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CNO | DNLI |
|---|---|---|
| Founded | 1979 | 2013 |
| Country | United States | United States |
| Employees | 3300 | N/A |
| Industry | Accident &Health Insurance | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | N/A | 2017 |
Fundamental Metrics
Financial Performance| Metric | CNO | DNLI |
|---|---|---|
| Price | $52.13 | $25.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 14 |
| Target Price | ★ $46.50 | $34.33 |
| AVG Volume (30 Days) | 803.6K | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.52% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.42 | $408.85 |
| P/E Ratio | $18.71 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $35.24 | $12.58 |
| 52 Week High | $53.03 | $26.80 |
Technical Indicators
Market Signals| Indicator | CNO | DNLI |
|---|---|---|
| Relative Strength Index (RSI) | 66.24 | 74.24 |
| Support Level | $39.04 | $18.07 |
| Resistance Level | $53.03 | N/A |
| Average True Range (ATR) | 0.99 | 1.15 |
| MACD | -0.05 | 0.24 |
| Stochastic Oscillator | 80.58 | 83.50 |
Price Performance
Historical ComparisonAbout CNO CNO Financial Group Inc.
CNO Financial Group Inc is a holding company for a group of insurance companies that develop, market and administer health insurance, annuity, individual life insurance and other insurance and financial services products. Consumers are served through the phone, online, mail, face-to-face with agents, or sales channels. The company's operating segments include annuity, health, and life insurance product lines as well as the investment and fee revenue segments. Maximum revenue is generated from the health product line segment. Annuity premiums account for the majority of the total premiums collected. Annuity products include fixed index annuities, traditional fixed-rate annuities, and single-premium immediate annuity products.
About DNLI Denali Therapeutics Inc.
Denali Therapeutics Inc is a biotechnology company that is engaged in developing and discovering therapeutics to defeat neurodegenerative diseases. The company's development programs include the LRRK2 Inhibitor Program, which develops brain penetrant small molecule LRRK2 inhibitor product candidates for Parkinson's disease. Its key products include DNL201, DNL151, ATV (Antibody Transport Vehicle), ETV (Enzyme Transport Vehicle), and others. The Company has one operating segment with the goal to discover, develop, and commercializing therapeutics.